Following on from the actions taken by a number of European countries to try to halt the spread of the COVID-19 pandemic, EORTC is liaising with its members to monitor the developments in their institutions and countries.
“Patient safety is paramount to us, and we will do everything we can to ensure that patients in trials still receive treatment for their disease,” says Dr Denis Lacombe, Director General of EORTC. “We will do whatever we can to safeguard the health and safety of patients on EORTC clinical trials, our staff, and our members. Our thoughts are with those families who have been greatly affected by this pandemic, and we will do all we can to help and protect them.”
“As Europe’s borders remain closed, we are watching the supply of cancer drugs for trials, as well any other emerging issues and limitations related to clinical research.”
EORTC continues to provide services and to ensure that there is minimal impact on its activities.